Join
Live feed
·
PRReleasevia Quantisnow
Replimune Group Inc. logo

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

ByQuantisnow·Wall Street's wire, on your screen.
REPL· Replimune Group Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REPL (Replimune Group Inc.) and more on Quantisnow.